search
Back to results

Gingival Crevicular Fluid, Salivary, and Serum Biomarkers Levels in Periodontal Treatment

Primary Purpose

Periodontal Health, Periodontitis

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Non-surgical periodontal treatment
Sponsored by
Marmara University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Periodontal Health focused on measuring periodontitis, periodontal treatment

Eligibility Criteria

30 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • systemically healthy and non-smoker individuals
  • having ≥20 teeth present (except third molars)
  • individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses

Exclusion Criteria:

  • having any diagnosed medical disorders
  • usage of antibiotics, non-steroidal anti-inflammatory drugs, and immunosuppressive agents within the past 6 months
  • having any non-inflammatory destructive periodontal disease
  • non-surgical/surgical periodontal therapy received in the past year
  • pregnant/ lactating/ postmenopausal females

Sites / Locations

  • Hatice Selin Yıldırım

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Active Comparator

Active Comparator

Arm Label

Periodontally Healthy

Stage III Grade B Periodontitis

Stage III Grade C Periodontitis

Arm Description

Systemically and periodontally healthy

The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.

The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.

Outcomes

Primary Outcome Measures

GCF IL-26 level (ng/ml)
Change in GCF IL-26 levels from baseline to 1 month and 3 months after treatment
GCF IL-6 level (ng/ml)
Change in GCF IL-6 levels from baseline to 1 month and 3 months after treatment
GCF IL-10 level (ng/ml)
Change in GCF IL-10 levels from baseline to 1 month and 3 months after treatment

Secondary Outcome Measures

Saliva IL-26 level (ng/ml)
Change in saliva IL-26 levels from baseline to 1 month and 3 months after treatment
Saliva IL-6 level (ng/ml)
Change in saliva IL-6 levels from baseline to 1 month and 3 months after treatment
Saliva IL-10 level (ng/ml)
Change in saliva IL-6 levels from baseline to 1 month and 3 months after treatment
Serum IL-26 level (ng/ml)
Change in serum IL-26 levels from baseline to 1 month and 3 months after treatment
Serum IL-6 level (ng/ml)
Change in serum IL-6 levels from baseline to 1 month and 3 months after treatment
Serum IL-10 level (ng/ml)
Change in serum IL-10 levels from baseline to 1 month and 3 months after treatment

Full Information

First Posted
May 24, 2022
Last Updated
May 24, 2022
Sponsor
Marmara University
search

1. Study Identification

Unique Protocol Identification Number
NCT05395455
Brief Title
Gingival Crevicular Fluid, Salivary, and Serum Biomarkers Levels in Periodontal Treatment
Official Title
Effect of Non-surgical Periodontal Treatment on Gingival Crevicular Fluid, Salivary and Serum Interleukin-26 Levels in Stage III Grade B and C Periodontitis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
November 12, 2018 (Actual)
Primary Completion Date
January 23, 2020 (Actual)
Study Completion Date
January 23, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Marmara University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The present study aimed to assess the effect of non-surgical periodontal treatment on gingival crevicular fluid (GCF), saliva, and serum IL-26, IL-6, and IL-10 levels in stage III grade B periodontitis (SIII-GB-P) and C periodontitis (SIII-GC-P) patients. 25 periodontally healthy, 25 SIII-GB-P, and 25 SIII-GC-P participants were enrolled. At baseline, GCF, saliva, and serum samples were collected and the whole mouth clinical periodontal parameters were recorded. Periodontitis patients received non-surgical periodontal treatment (NSPT). Clinical parameters and samples were re-collected at 1 and 3 months after NSPT. GCF, saliva, and serum IL-26, IL-6, and IL-10 were analyzed by ELISA. Data were analyzed using appropriate statistical tests.
Detailed Description
Periodontitis is an inflammatory process that can result in tooth loss by destroying teeth-supporting tissues. Interleukin (IL) 26, is one of the recent members of the IL-10 cytokine family. The elevated level of IL-26 expression is associated with inflammatory disorders. IL-6, a pro-inflammatory cytokine and is one of the important molecules in the regulation of inflammatory immune responses in periodontitis. IL-10, an anti-inflammatory cytokine, affects monocytes and macrophages and their immune mediator release. This study is the first controlled clinical study that examines the levels of IL-26 in GCF, saliva, and serum in two different periodontitis, and evaluates the situation before and after the treatment. The first hypothesis of this study GCF, salivary, and serum IL-26 and IL-6 levels will be high and GCF, salivary and serum IL-10 will be low in periodontitis groups, in contrast to the periodontal health the second hypothesis of this study is that after periodontal treatment, GCF, saliva, and serum IL-26 and IL-6 will decrease and GCF, saliva, and serum IL-10 will increase. Based on these hypotheses, the aim of the study is; to compare the levels of IL-26, IL-6, and IL-10 in GCF, saliva, and serum of healthy controls, SIII-GB-P, and SIII-GC-P subjects and to evaluate the effect of periodontal treatment. A total of 75 systemically healthy patients; 25 periodontally healthy, 25 SIII-GB-P, and 25 SIII-GC-P were included in this study. The clinical periodontal examination, including measurement of probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI), and plaque index (PI) was performed at 6 sites per tooth, except the third molars. The presence of alveolar bone loss was assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary. The periodontal status of each patient was evaluated by a single calibrated periodontist with a manual probe. The diagnosis of periodontitis or periodontally health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Periodontally healthy individuals (n=25) in the control group had no sites with PD >3 mm and CAL >2 mm and also no radiographic evidence of alveolar bone loss. BOP was <10% in the whole mouth and exhibited no history of periodontitis. The periodontitis stage III patients had a minimum of 3 teeth apart from the first molars and incisors showing CAL ≥5 mm and PD ≥6 mm and showed no>4 teeth loss caused by periodontitis. The radiographic bone loss extends from coronal to middle third or beyond. Radiographic bone loss was determined from the tooth showing the most severe bone loss as a percentage of root length. If the values of bone loss %/age were between 0.25 and 1.0, the patients were assigned to grade B (n=25). If higher than 1.0, the patients were assigned to grade C (n=25). Treatment The periodontitis patients received conventional scaling and root planning (SRP) under local anesthesia in a total of 4 sessions in two weeks. SRP was performed by the same periodontist using ultrasonic inserts and manual periodontal curettes. Re-evaluations were performed at 1 and 3 months following the completion of the treatment. GCF, Saliva and Serum Sampling Filter paper strips were used to collect GCF samples. In the healthy control group, GCF was collected from the interproximal sites of single-rooted and multiple rooted teeth from each quadrant. GCF was collected from the sites with PD ≥ 6 mm and radiographic bone loss in periodontitis groups. Selected sites were isolated with cotton rolls. The paper strip was removed after 30 sec after inserting the periodontal pocket. A total of 5 mL of unstimulated whole saliva was collected by the passive drool method in the morning. The saliva was collected over a period of 5 minutes with instructions to pool saliva on the floor of the mouth and passively drool it into a sterile glass beaker and samples are immediately transferred to a 2 mL polypropylene tube. A total of 5 mL of blood was collected from the antecubital fossa by venepuncture method. Serum was isolated from the blood by centrifuging at 5000 rpm for 10 minutes followed by its rapid transfer to a sterile polypropylene tube. All the samples were stored at -80°C. Biomarker Immunoassays GCF, saliva, and serum samples were thawed on ice. The saliva samples were centrifuged at 5.000 rpm for 15 minutes at room temperature, and supernatants were immediately used for assays. GCF, serum, and salivary samples of IL-26, IL-10, and IL-6 were measured by ELISA using commercial kits. Statistical Analysis All statistical analyses were carried out with the standard statistical software package. For the intra-group comparisons, if the data were not normally disturbed, the Friedman test and the Dunn test with the Bonferroni correction were used to analyze the change between baseline and 1 month and 3 months after treatment. For inter-group comparisons, the Mann-Whitney U test was performed. The Spearman's rank correlation test was used to detect the correlations of biochemical parameters with clinical parameters and each other in periodontitis group before and after treatment. All tests were performed at a significance level of p<0.05.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontal Health, Periodontitis
Keywords
periodontitis, periodontal treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
75 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Periodontally Healthy
Arm Type
No Intervention
Arm Description
Systemically and periodontally healthy
Arm Title
Stage III Grade B Periodontitis
Arm Type
Active Comparator
Arm Description
The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Arm Title
Stage III Grade C Periodontitis
Arm Type
Active Comparator
Arm Description
The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Intervention Type
Procedure
Intervention Name(s)
Non-surgical periodontal treatment
Intervention Description
Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
Primary Outcome Measure Information:
Title
GCF IL-26 level (ng/ml)
Description
Change in GCF IL-26 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Title
GCF IL-6 level (ng/ml)
Description
Change in GCF IL-6 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Title
GCF IL-10 level (ng/ml)
Description
Change in GCF IL-10 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Secondary Outcome Measure Information:
Title
Saliva IL-26 level (ng/ml)
Description
Change in saliva IL-26 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Title
Saliva IL-6 level (ng/ml)
Description
Change in saliva IL-6 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Title
Saliva IL-10 level (ng/ml)
Description
Change in saliva IL-6 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Title
Serum IL-26 level (ng/ml)
Description
Change in serum IL-26 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Title
Serum IL-6 level (ng/ml)
Description
Change in serum IL-6 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment
Title
Serum IL-10 level (ng/ml)
Description
Change in serum IL-10 levels from baseline to 1 month and 3 months after treatment
Time Frame
Baseline to 1 month and 3 months after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: systemically healthy and non-smoker individuals having ≥20 teeth present (except third molars) individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses Exclusion Criteria: having any diagnosed medical disorders usage of antibiotics, non-steroidal anti-inflammatory drugs, and immunosuppressive agents within the past 6 months having any non-inflammatory destructive periodontal disease non-surgical/surgical periodontal therapy received in the past year pregnant/ lactating/ postmenopausal females
Facility Information:
Facility Name
Hatice Selin Yıldırım
City
Istanbul
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Gingival Crevicular Fluid, Salivary, and Serum Biomarkers Levels in Periodontal Treatment

We'll reach out to this number within 24 hrs